RBC Capital analyst Gregory Renza maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) yesterday and set a price target of $176.00. The company’s shares closed yesterday at $110.31.
According to TipRanks, Renza is a 5-star analyst with an average return of 18.1% and a 45.15% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Exelixis, and Jazz Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $188.67 average price target, implying a 71.04% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $222.00 price target.
JAZZ market cap is currently $6.95B and has a P/E ratio of 19.11.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals (JAZZ) Company Description:
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Read More on JAZZ:
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Baird starts Praxis Precision at Outperform on ulixacaltamide’s potential
- JAZZ Earnings this Week: How Will it Perform?
- Jazz completes rolling submission of BLA for zanidatamab antibody
- Jazz Pharmaceuticals price target raised to $188 from $171 at Piper Sandler
